We’ve recently updated our valuation analysis.

TG Therapeutics Valuation

Is TGTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TGTX?

Other financial metrics that can be useful for relative valuation.

TGTX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue371.2x
Enterprise Value/EBITDA-8x
PEG Ration/a

Price to Book Ratio vs Peers

How does TGTX's PB Ratio compare to its peers?

The above table shows the PB ratio for TGTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average455.7x
RCUS Arcus Biosciences
2.4x6.1%US$1.7b
DVAX Dynavax Technologies
3x-25.2%US$1.5b
SNDX Syndax Pharmaceuticals
5.7x47.2%US$1.9b
VSBC VitaSpring Biomedical
1811.8xn/aUS$3.0b
TGTX TG Therapeutics
19.5x53.3%US$2.0b

Price-To-Book vs Peers: TGTX is good value based on its Price-To-Book Ratio (19.5x) compared to the peer average (455.7x).


Price to Earnings Ratio vs Industry

How does TGTX's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.1%
n/an/an/a

Price-To-Book vs Industry: TGTX is expensive based on its Price-To-Book Ratio (19.5x) compared to the US Biotechs industry average (1.8x)


Price to Book Ratio vs Fair Ratio

What is TGTX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TGTX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio19.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate TGTX's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of TGTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TGTX ($14.63) is trading below our estimate of fair value ($104.01)

Significantly Below Fair Value: TGTX is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TGTX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$14.63
US$19.11
+30.6%
38.4%US$26.00US$6.00n/a9
Jan ’24US$11.83
US$18.13
+53.2%
41.4%US$26.00US$6.00n/a8
Dec ’23US$8.02
US$17.56
+118.9%
57.7%US$40.00US$4.00n/a9
Nov ’23US$6.28
US$17.22
+174.2%
58.2%US$40.00US$4.00n/a9
Oct ’23US$5.92
US$17.22
+190.9%
58.2%US$40.00US$4.00n/a9
Sep ’23US$7.36
US$17.22
+134.0%
58.2%US$40.00US$4.00n/a9
Aug ’23US$5.54
US$17.22
+210.9%
58.2%US$40.00US$4.00n/a9
Jul ’23US$4.57
US$17.22
+276.9%
58.2%US$40.00US$4.00n/a9
Jun ’23US$3.91
US$17.89
+357.5%
56.9%US$40.00US$4.00n/a9
May ’23US$6.94
US$19.63
+182.8%
48.2%US$40.00US$5.00n/a8
Apr ’23US$10.08
US$38.25
+279.5%
44.3%US$68.00US$8.00n/a8
Mar ’23US$10.29
US$41.13
+299.7%
45.4%US$68.00US$7.00n/a8
Feb ’23US$11.77
US$45.75
+288.7%
39.3%US$68.00US$13.00n/a8
Jan ’23US$19.00
US$48.63
+155.9%
35.0%US$75.00US$13.00US$11.838
Dec ’22US$15.69
US$48.63
+209.9%
35.0%US$75.00US$13.00US$8.028
Nov ’22US$32.73
US$59.88
+82.9%
23.5%US$84.00US$33.00US$6.288
Oct ’22US$33.71
US$59.88
+77.6%
23.5%US$84.00US$33.00US$5.928
Sep ’22US$29.46
US$59.88
+103.2%
23.5%US$84.00US$33.00US$7.368
Aug ’22US$34.99
US$72.75
+107.9%
18.6%US$91.00US$46.00US$5.548
Jul ’22US$40.45
US$72.75
+79.9%
18.6%US$91.00US$46.00US$4.578
Jun ’22US$34.46
US$72.75
+111.1%
18.6%US$91.00US$46.00US$3.918
May ’22US$44.71
US$73.38
+64.1%
17.1%US$91.00US$50.00US$6.948
Apr ’22US$48.96
US$74.29
+51.7%
11.7%US$91.00US$65.00US$10.087
Mar ’22US$45.00
US$75.14
+67.0%
12.9%US$95.00US$65.00US$10.297
Feb ’22US$48.47
US$68.14
+40.6%
6.6%US$78.00US$63.00US$11.777
Jan ’22US$52.02
US$61.00
+17.3%
12.9%US$70.00US$47.00US$19.007

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies